Sorrento Therapeutics (NASDAQ:SRNE) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a report issued on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Stock Down 31.5 %

SRNE stock opened at $0.01 on Monday. The business has a 50-day simple moving average of $0.02 and a 200 day simple moving average of $0.05. Sorrento Therapeutics has a 52 week low of $0.00 and a 52 week high of $0.42.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.